EU/3/08/546: Orphan designation for the treatment of congenital alpha-1 antitrypsin deficiency

Table of contents


On 3 June 2008, orphan designation (EU/3/08/546) was granted by the European Commission to Talecris Biotherapeutics GmbH, Germany, for alpha-1 proteinase inhibitor (for inhalation use) for the treatment of congenital alpha-1 antitrypsin deficiency.

In February 2012, Talecris Biotherapeutics GmbH changed name to Grifols Deutschland GmbH.

Key facts

Intended use
Treatment of congenital alpha-1 antitrypsin deficiency
Orphan designation status
EU designation number
Date of designation
Grifols Deutschland GmbH
Colmarer Strasse 22
D-60528 Frankfurt am Main
Tel. + +49 69 66 05 93 401

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating